ACLS Provider: Course

Incorrect. If VF persists after defibrillation and epinephrine, amiodarone is administered to stabilize the rhythm.

Incorrect. A compression fraction above 80% ensures that most of the resuscitation time is spent performing chest compressions.

Incorrect. Placing hands on the lower half of the sternum ensures effective chest compressions without damaging other structures.

Incorrect. Hypothermia is a reversible cause of cardiac arrest and is treated by warming the patient to improve outcomes.

Incorrect. Epinephrine is given every 3-5 minutes to enhance coronary and cerebral perfusion during cardiac arrest.

Incorrect. PETCO2 monitoring provides real-time feedback on ventilation and the effectiveness of chest compressions.

Incorrect. Maintaining a compression fraction of greater than 80% ensures the majority of resuscitation time is spent on compressions.

Incorrect. Atropine is the first-line drug for treating symptomatic bradycardia by increasing heart rate through vagal inhibition.

Incorrect. Epinephrine is given at a dose of 1 mg IV/IO every 3-5 minutes during adult cardiac arrest to improve perfusion.

Incorrect. Atropine should not exceed a total dose of 3 mg when treating symptomatic bradycardia in adults.

Incorrect. Epinephrine is the first-line drug for VF, with amiodarone as the preferred antiarrhythmic for refractory cases.

Incorrect. Pediatric defibrillation begins at 2 J/kg and increases to 4 J/kg for subsequent shocks if needed.

Incorrect. Compressing 2-2.4 inches ensures effective perfusion during adult CPR while minimizing the risk of injury.

Incorrect. PEA is treated with CPR and epinephrine, as defibrillation is ineffective for non-shockable rhythms.

Incorrect. Avoid delays to minimize interruptions in chest compressions and maintain perfusion.

Incorrect. PEA is treated with epinephrine and high-quality CPR to address underlying reversible causes.

Incorrect. Defibrillation is the priority for VF and should not be delayed for drug administration, as it is the definitive treatment.

Incorrect. Synchronized cardioversion is indicated for unstable atrial fibrillation to restore sinus rhythm and prevent hemodynamic collapse.

Incorrect. Magnesium sulfate stabilizes the myocardium and is the drug of choice for torsades de pointes.

Incorrect. Rescuers should switch every 2 minutes to prevent fatigue and ensure high-quality compressions are maintained.

Incorrect. The maximum dose of atropine for bradycardia is 3 mg, with doses given at 0.5 mg intervals every 3-5 minutes.

Incorrect. Naloxone blocks opioid receptors and is administered to reverse opioid overdose and restore adequate respiration.

Incorrect. Minimizes interruptions to maintain blood flow to vital organs.

Incorrect. Maintaining a compression fraction above 80% ensures adequate blood flow during resuscitation.

Incorrect. Delivering 6-8 breaths per minute minimizes interruptions in chest compressions and prevents hyperventilation.

Incorrect. The jaw thrust technique opens the airway while minimizing cervical spine movement, reducing the risk of further injury.

Incorrect. Magnesium sulfate is the first-line treatment for torsades de pointes as it stabilizes the myocardium.

Incorrect. Hypothermia is a reversible cause of cardiac arrest and should be addressed during resuscitation efforts.

Incorrect. A rate of 100-120 compressions per minute ensures adequate circulation without risking incomplete recoil or excessive fatigue.

Incorrect. Hypovolemia is a reversible cause of cardiac arrest and should be corrected with fluid resuscitation.

Incorrect. Administered every 3-5 minutes to restore circulation by increasing coronary and cerebral perfusion pressure.

Incorrect. For unstable narrow, irregular tachycardias, synchronized cardioversion at 120-200 J is recommended.

Incorrect. Epinephrine is administered every 3-5 minutes during cardiac arrest to maximize coronary and cerebral perfusion.

Incorrect. Optimal for maintaining adequate circulation without risking poor perfusion due to excessive speed.

Incorrect. PEA is not a shockable rhythm; it is managed with high-quality CPR and addressing the underlying reversible causes.

Incorrect. Calcium gluconate stabilizes the cardiac membrane and reduces the risk of life-threatening arrhythmias caused by hyperkalemia.

Incorrect. Atrial flutter presents as a sawtooth pattern on the ECG and requires rate control or cardioversion depending on stability.

Incorrect. Maximum energy for monophasic defibrillators; for biphasic, follow manufacturer recommendations.

Incorrect. CPR is the primary treatment for PEA, along with epinephrine and addressing reversible causes to restore circulation.

Incorrect. Oxygen saturation should be maintained at 92-96% to avoid hypoxia and reduce the risk of hyperoxia and oxidative stress.

Incorrect. Biphasic defibrillators deliver effective shocks within the range of 120-200 J to treat VF or pulseless VT.

Incorrect. Epinephrine is administered every 3-5 minutes during pediatric cardiac arrest to enhance coronary and cerebral perfusion.

Incorrect. Shouting for help ensures additional resources and a defibrillator are quickly available.

Incorrect. Stabilizes the myocardium and suppresses arrhythmias during refractory VF or pulseless VT.

Incorrect. Ventricular fibrillation (VF) is a shockable rhythm and requires immediate defibrillation to restore an organized rhythm.

Incorrect. Asystole is a non-shockable rhythm and is treated with high-quality CPR and epinephrine administration.

Incorrect. PEA is not treated with adenosine; it is managed with CPR, epinephrine, and identifying and treating reversible causes.

Incorrect. Compressing to one-third the depth of the chest ensures adequate perfusion while minimizing the risk of injury.

Incorrect. Rotating team roles every 2 minutes prevents fatigue, ensuring consistent delivery of high-quality chest compressions.

Incorrect. Hypoxia is one of the most common reversible causes of PEA and is addressed with high-quality oxygenation during resuscitation.

Incorrect. Pediatric defibrillation starts at 2 J/kg for the initial shock, increasing as needed based on the patient's response.

Incorrect. Naloxone reverses opioid-induced respiratory depression, restoring normal respiratory function.

Incorrect. Magnesium sulfate is used to treat torsades de pointes but is not the first-line drug for VF, where epinephrine is prioritized.

Incorrect. Atropine is the first-line treatment for symptomatic bradycardia, increasing the heart rate by blocking vagal stimulation.

Incorrect. Oxygen saturation should be maintained at 92-96% to prevent hypoxia and avoid the harmful effects of hyperoxia.

Incorrect. These shockable rhythms require immediate defibrillation to restore a perfusing rhythm.

Incorrect. Providing 6-8 breaths per minute ensures adequate oxygenation and ventilation without interfering with chest compressions.

Incorrect. Pulseless VT is treated with defibrillation, not atropine. Atropine is used for symptomatic bradycardia.

Incorrect. Pediatric defibrillation starts at 2 J/kg to safely deliver an effective shock without causing harm.

Incorrect. Symptomatic second-degree AV block type II can progress to complete heart block, requiring pacing.

Incorrect. With an advanced airway in place, compressions should continue uninterrupted while providing 10 breaths per minute.

Incorrect. The correct initial dose of amiodarone for pulseless VT is 300 mg IV/IO, followed by 150 mg for a second dose if needed.

Incorrect. Epinephrine is repeated every 3-5 minutes during cardiac arrest to enhance perfusion pressure.

Incorrect. A 15:2 ratio is used during pediatric CPR with two rescuers to optimize ventilation and circulation.

Incorrect. Epinephrine 1 mg IV/IO is administered every 3-5 minutes during cardiac arrest to improve coronary and cerebral perfusion.